company background image
ITOS

iTeos TherapeuticsNasdaqGM:ITOS Stock Report

Last Price

US$39.66

Market Cap

US$1.4b

7D

-7.8%

1Y

12.9%

Updated

16 Jan, 2022

Data

Company Financials +
ITOS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

ITOS Stock Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.

Price History & Performance

Summary of all time highs, changes and price drops for iTeos Therapeutics
Historical stock prices
Current Share PriceUS$39.66
52 Week HighUS$52.43
52 Week LowUS$17.43
Beta0
1 Month Change-8.19%
3 Month Change43.54%
1 Year Change12.90%
3 Year Changen/a
5 Year Changen/a
Change since IPO108.19%

Recent News & Updates

Nov 25
Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Celebrations may be in order for iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders, with the analysts delivering a...

Shareholder Returns

ITOSUS BiotechsUS Market
7D-7.8%-1.2%-0.5%
1Y12.9%-14.3%13.7%

Return vs Industry: ITOS exceeded the US Biotechs industry which returned -14.3% over the past year.

Return vs Market: ITOS matched the US Market which returned 13.7% over the past year.

Price Volatility

Is ITOS's price volatile compared to industry and market?
ITOS volatility
ITOS Average Weekly Movement8.0%
Biotechs Industry Average Movement10.0%
Market Average Movement6.6%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: ITOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ITOS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201174Michel Detheuxhttps://www.iteostherapeutics.com

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company’s product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

iTeos Therapeutics Fundamentals Summary

How do iTeos Therapeutics's earnings and revenue compare to its market cap?
ITOS fundamental statistics
Market CapUS$1.40b
Earnings (TTM)US$14.75m
Revenue (TTM)US$104.27m

94.9x

P/E Ratio

13.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ITOS income statement (TTM)
RevenueUS$104.27m
Cost of RevenueUS$0
Gross ProfitUS$104.27m
ExpensesUS$89.53m
EarningsUS$14.75m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.42
Gross Margin100.00%
Net Profit Margin14.14%
Debt/Equity Ratio0%

How did ITOS perform over the long term?

See historical performance and comparison

Valuation

Is iTeos Therapeutics undervalued compared to its fair value and its price relative to the market?

94.88x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ITOS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ITOS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ITOS is poor value based on its PE Ratio (94.9x) compared to the US Biotechs industry average (24.4x).

PE vs Market: ITOS is poor value based on its PE Ratio (94.9x) compared to the US market (17.4x).


Price to Earnings Growth Ratio

PEG Ratio: ITOS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: ITOS is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (2.2x).


Future Growth

How is iTeos Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-54.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ITOS's earnings are forecast to decline over the next 3 years (-54.5% per year).

Earnings vs Market: ITOS's earnings are forecast to decline over the next 3 years (-54.5% per year).

High Growth Earnings: ITOS's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ITOS's revenue is expected to decline over the next 3 years (-16.9% per year).

High Growth Revenue: ITOS's revenue is forecast to decline over the next 3 years (-16.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ITOS's Return on Equity is forecast to be low in 3 years time (0.5%).


Past Performance

How has iTeos Therapeutics performed over the past 5 years?

22.5%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: ITOS has high quality earnings.

Growing Profit Margin: ITOS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ITOS has become profitable over the past 5 years.

Accelerating Growth: ITOS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ITOS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: ITOS's Return on Equity (4%) is considered low.


Financial Health

How is iTeos Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ITOS's short term assets ($914.1M) exceed its short term liabilities ($542.2M).

Long Term Liabilities: ITOS's short term assets ($914.1M) exceed its long term liabilities ($8.1M).


Debt to Equity History and Analysis

Debt Level: ITOS is debt free.

Reducing Debt: ITOS has not had any debt for past 5 years.

Debt Coverage: ITOS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ITOS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is iTeos Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ITOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ITOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ITOS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ITOS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ITOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Michel Detheux (55 yo)

10.42yrs

Tenure

US$16,816,531

Compensation

Dr. Michel Detheux, Ph D, serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021. He has served as the Chief Executive Officer and Director at iTeos Therapeutics, Inc. since August...


CEO Compensation Analysis

Compensation vs Market: Michel's total compensation ($USD16.82M) is above average for companies of similar size in the US market ($USD3.62M).

Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ITOS's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: ITOS's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ITOS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

iTeos Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: iTeos Therapeutics, Inc.
  • Ticker: ITOS
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.399b
  • Shares outstanding: 35.27m
  • Website: https://www.iteostherapeutics.com

Number of Employees


Location

  • iTeos Therapeutics, Inc.
  • 139 Main Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/16 23:14
End of Day Share Price2022/01/14 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.